Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine

At its September 21 Capital Markets Day, Novo Nordisk A/S outlined plans to launch more than five multi-blockbusters by 2030 and deliver over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar said Novo will prioritize asset quality over deal size, with bolt-on acquisitions likely to be the focus while remaining open to larger deals.

Meanwhile, in Q2, sales of the Wegovy pill were up 42.6% quarter-on-quarter to about DKK 3.2 billion. And "rare endocrine disorders" generated DKK 1.54 billion for Novo, up 8.3% YoY and 34.1% QoQ.

In this article, you'll learn why I continue to cover NVO stock with a Strong Buy rating.